June 2018

The updated guidelines recommend targeting those with active infection and avoiding treatment of “carriers” of C difficile who are colonized but not symptomatic.

Although challenging, it is not impossible to change some outlier behaviors.

The rise of ID pharmacy as a profession has been complementary to services uniquely offered by ID physicians, not in competition with them.

MJH Associates, Inc & the FDA are both committed to eliminating inefficiencies and hype to deliver the most timely and relevant information to health care providers.

Preliminary studies provide convincing evidence for the synergistic use of sulfonamide agents with azole antifungals.

Because of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.

Experts continue to recommend that people get the seasonal flu vaccine as the scientific community works toward a universal vaccine offering lifelong protection against multiple strains.

Early diagnosis and treatment were essential to ensuring a good prognosis.

The emergence of new species creates pressure for developing affordable and reliable diagnostic strategies.

Patient and institutional history, as well as the individual niches of the new antibiotics, need to be considered when selecting a treatment for gram-negative infections.

Several recent studies provide valuable insight surrounding the appropriateness of transitioning from intravenous to oral therapy when treating bacteremic urinary tract infections.

Implants are promising for long-term, sustained, and reversible delivery of ARV drugs that may bypass adherence challenges for end users.

An increase in injection drug use in the United States has augmented the likelihood of acquiring HCV, particularly genotype 3.